Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

J. T. Hutton, W. C. Koller, J. E. Ahlskog, R. Pahwa, H. I. Hurtig, M. B. Stern, B. C. Hiner, A. Lieberman, R. F. Pfeiffer, R. L. Rodnitzky, C. H. Waters, M. D. Muenter, C. H. Adler, J. L. Morris

Research output: Contribution to journalArticle

86 Scopus citations

Abstract

Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the 'on' state increased more in the cabergoline group (p = 0.022). The side-effect profile was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.

Original languageEnglish (US)
Pages (from-to)1062-1065
Number of pages4
JournalNeurology
Volume46
Issue number4
DOIs
StatePublished - Apr 1996

    Fingerprint

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Hutton, J. T., Koller, W. C., Ahlskog, J. E., Pahwa, R., Hurtig, H. I., Stern, M. B., Hiner, B. C., Lieberman, A., Pfeiffer, R. F., Rodnitzky, R. L., Waters, C. H., Muenter, M. D., Adler, C. H., & Morris, J. L. (1996). Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology, 46(4), 1062-1065. https://doi.org/10.1212/WNL.46.4.1062